TRPV4 and cancer: We found that the IC50 values of several anti-cancer drugs decreased in the high-TRPV4 group, including sapitinib (an EGFR inhibitor) and selumetinib (a MEK1/2 inhibitor) (Figure 8A), indicating that patients exhibiting high TRPV4 expression levels are relatively sensitive to these anti-cancer drugs.